All In Biotech

Drug Trial Radar · NCT02466204

Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients

An Efficacy and Safety Study of Corifollitropin Alfa Versus Daily Follitropin Beta for Controlled Ovarian Stimulation in Women 35-42 Years Old With a Body Weight ≥ 50 kg Undergoing IVF Treatment.

Last checked: Nov 20, 2026Latest source record: Aug 22, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Jun 1, 2015

Primary completion

Aug 10, 2016

Study completion Aug 15, 2017

Sponsor

Lead sponsor
Vietnam National UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Sharp & Dohme LLC; Mỹ Đức Hospital
First posted
Jun 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 35 years, up to 42 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, randomized, controlled study to explore the efficacy and safety of using either corifollitropin alfa 150 mcg or daily recombinant follicle stimulation hormone (FSH) 300 international unit (IU) for the stimulation treatment of subjects undergoing controlled ovarian stimulation prior to IVF. The study is designed as a non-inferiority trial. The sample size for this trial of 400 subjects, in both groups, being treated for one IVF cycle is based upon the primary endpoint of the number of oocytes retrieved.

Conditions

  • Infertility

Interventions

  • corifollitropin alfaDrug

    Drug is injected subcutaneously. Seven days after, 300 IU FSH daily injected subcutaneously, until at least two leading ovarian follicles reach 17mm in diameter.

  • Follitropin BetaDrug

    Drug is injected subcutaneously, daily, until at least two leading ovarian follicles reach 17mm in diameter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. number of oocytesTime frame: 10 minutes after oocyte retrieval completed

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • My Duc Hospital

    Ho Chi Minh City, Vietnam

  • Research Center for Genetics and Reproductive Health

    Ho Chi Minh City, Vietnam

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.